Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and individualized dosing of antimicrobial agents in critically ill patients with severe infections
ChiCTR2500103320Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of teicoplanin, tigecycline, caspofungin, omadacycline, meropenem and 2 more in Infection (7 arms), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: Plasma concentration of antimicrobial agents. Planned start May 2025; status: not yet recruiting.
02
Drugs
teicoplanintigecyclinecaspofunginomadacyclinemeropenem
03
Conditions
Infection
Beyond the preview
Go deeper on ChiCTR2500103320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103320.